Each 1-hour session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for AML. Each event will employ an identical format that will include the following elements:

• • Discussion of Steering Committee Members’ Treatment Recommendations
• • Review of Available Clinical Research Findings
• • Integration of Interactive Audience Polling Results

Each session will conclude with a 5-minute Q&A segment on current clinical care in the age of COVID-19.

Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of AML.

Learning Objectives

• Understand the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine diagnostic testing algorithms for patients with AML.
• Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
• Recognize the FDA approval of venetoclax for patients with newly diagnosed AML unfit for intensive therapy, and discern how this agent can be optimally integrated into nonresearch care algorithms.
• Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Develop an understanding of the mechanism of action of, available data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation.
• Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with the use of recently approved systemic therapies in the management of AML to support quality of life and continuation of therapy.

CME Credit Form
An online CME credit form will be made available to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support
These activities are supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc and Astellas.

STEERING COMMITTEE MEMBERS